MannKind Corporation announced a strong close to 2025, achieving a record-setting fourth quarter with net revenue surpassing $100 million. The company highlighted its acquisition of scPharmaceuticals as a significant milestone reinforcing its growth trajectory. For 2026, MannKind outlined several anticipated growth drivers, including two high-potential product launches. Key upcoming catalysts include an FDA decision on an Afrezza® label update, with a target action date of January 23, 2026, and a supplemental Biologics License Application for pediatric use of Afrezza®, with a target action date of May 29, 2026. Additionally, a supplemental New Drug Application for the FUROSCIX ReadyFlow™ Autoinjector is under FDA review, with a PDUFA target action date of July 26, 2026. MannKind also reported progress in its clinical pipeline, including the enrollment of the first patient in the INFLO-1 Phase 1b study for Nintedanib DPI and anticipated advancement in further studies and collaborations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9621996) on January 08, 2026, and is solely responsible for the information contained therein.